PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1536.00 - 1565.00
1090.00 - 1784.00
46.2K / 155.6K (Avg.)
23.48 | 66.41
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
33.01%
Revenue growth above 1.5x 5715.T's 7.81%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
2.27%
Gross profit growth under 50% of 5715.T's 13.84%. Michael Burry would be concerned about a severe competitive disadvantage.
3437.74%
EBIT growth above 1.5x 5715.T's 141.21%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
-90.62%
Negative operating income growth while 5715.T is at 30.99%. Joel Greenblatt would press for urgent turnaround measures.
1636.83%
Net income growth above 1.5x 5715.T's 163.45%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
1636.88%
EPS growth above 1.5x 5715.T's 163.44%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
1636.88%
Diluted EPS growth above 1.5x 5715.T's 163.44%. David Dodd would see if there's a robust moat protecting these shareholder gains.
-0.00%
Share reduction while 5715.T is at 0.00%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-93.78%
Both companies have negative long-term revenue/share growth. Martin Whitman would question if the entire market or product set is shrinking.
-37.77%
Both face negative 5Y revenue/share CAGR. Martin Whitman would suspect macro headwinds or obsolete product offerings across the niche.
-30.47%
Both firms have negative 3Y CAGR. Martin Whitman would wonder if the entire market segment is in short-term retreat.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
115.89%
Net income/share CAGR at 50-75% of 5715.T's 230.80%. Martin Whitman might question if the firm’s product or cost base lags behind.
197.59%
Below 50% of 5715.T's 1530.51%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
355.48%
3Y net income/share CAGR above 1.5x 5715.T's 98.50%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
No Data
No Data available this quarter, please select a different quarter.
184.50%
5Y equity/share CAGR above 1.5x 5715.T's 82.24%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
35.65%
3Y equity/share CAGR at 75-90% of 5715.T's 43.69%. Bill Ackman pushes for margin or operational changes to match the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
76.26%
AR growth well above 5715.T's 11.08%. Michael Burry fears inflated revenue or higher default risk in the near future.
159.90%
We show growth while 5715.T is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
92.27%
Asset growth above 1.5x 5715.T's 3.96%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
13.38%
BV/share growth above 1.5x 5715.T's 3.95%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
331.15%
We have some new debt while 5715.T reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
-100.00%
Our R&D shrinks while 5715.T invests at 0.00%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
99.74%
SG&A growth well above 5715.T's 6.84%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.